Resilience-h2020

RESILIENCE Proyect

A European Commission-funded project aimed at reducing the incidence of heart failure in cancer survivors

Cancer survivors are at high risk for cardiovascular complications. Anthracyclines are an extremely effective treatment against many cancer types, but they can induce cardiac toxicity resulting in chronic heart failure.

RESILIENCE Project tests a novel preventive intervention (remote ischemic conditioning) in patients at risk for anthracycline-induced cardiotoxicity. In addition, new diagnostic modalities will be used to identify anthracyclines-induced cardiotoxicity in its very early stages.

RESILIENCE counts on a multidisciplinary consortium with the active participation of patients.